In order to determine optimal CsA trough blood concentrations (TBC) in the early post transplantation period, we analysed relationships between TBC and acute graft-versus-host disease (aGVHD) in paediatric SCT. A total of 94 children consecutively underwent allogeneic stem cell transplantation (SCT) from: matched-sibling (MSD) (n ¼ 36), mismatched-related (MMRD) (n ¼ 3) and unrelated donors (UD) (n ¼ 55). GVHD prophylaxis usually included CsA alone or with methotrexate. Antithymocyte globulin was added in UD-SCT. TBC during the first weeks of post transplantation were estimated retrospectively by a Bayesian pharmacokinetic method and statistically associated with aGVHD. In MSD-SCT, the mean TBC during the first 2 weeks post transplantation were 42710 and 9077 ng/ml, respectively, in patients with grade II-IV and 0-I aGVHD (P ¼ 0.001). In SCT from UD and MMRD, TBC were 7374 vs 9578 ng/ml (P ¼ 0.284). For TBC 485 ng/ml, no patient developed grade II-IV aGVHD, 10 developed mild aGVHD and 30 had no aGVHD. For TBC o65 ng/ ml, 7/11 patients receiving an MSD-SCT and 4/18 receiving an UD-or MMRD-SCT developed grade II-IV aGVHD. The mean TBC corresponding to each grade were: no GVHD: 101710 ng/ml, mild: 77711 ng/ml, moderate: 61713 ng/ml, severe: 56715 ng/ml (Po0.001). These results reveal a strong relationship between TBC during the early post transplantation period and the severity of aGVHD in paediatric SCT. Bone Marrow Transplantation (2003) 32, 777-784. doi:10.1038/sj.bmt.1704213 Keywords: acute GVHD; stem cell transplantation; cyclosporine; paediatrics; Bayesian modelling Allogeneic stem cell transplantation (SCT) is curative in several malignant haematological diseases, aplastic anaemia, inborn errors of metabolism and immunodeficiencies. Unfortunately, the success of allogeneic SCT is offset by leukaemia relapses and transplant-related mortality (TRM) due to graft-versus-host disease (GVHD), toxicity of the conditioning regimen and infectious complications. Numerous risk factors for the development of acute GHVD (aGVHD) have been identified.
Allogeneic stem cell transplantation (SCT) is curative in several malignant haematological diseases, aplastic anaemia, inborn errors of metabolism and immunodeficiencies. Unfortunately, the success of allogeneic SCT is offset by leukaemia relapses and transplant-related mortality (TRM) due to graft-versus-host disease (GVHD), toxicity of the conditioning regimen and infectious complications. Numerous risk factors for the development of acute GHVD (aGVHD) have been identified. [1] [2] [3] [4] Even if there have recently been many advances in prophylaxis, aGVHD continues to account for significant morbidity and mortality after BMT. 3, 4 Although aGVHD is less frequent 1 and less severe 5 in younger patients than in adults, grade II-IV aGVHD incidence was 35% in paediatric-matched sibling donor-BMT (MSD-BMT), using a fixed cyclosporine A (CsA) dosing regimen. 5 The risk of aGVHD is strongly increased in paediatric unrelated donor-BMT (UD-BMT) requiring intensive immunosuppressive therapy. 6 However, Souillet et al 7 reported only 26% of grade II-IV aGVHD using in vivo T-cell depletion associated with CsA and MTX, despite a majority of HLA-mismatched donors in their cohort.
Although aGVHD can result in mortality, the major cause of failure and death following paediatric SCT for malignant disease, is leukaemia relapse: relapse rate (RR) reaches 41% in MSD-BMT using a fixed CsA regimen (3 mg/kg/day intravenously followed by 6 mg/kg/day orally) 8 and 37% in UD-BMT. 9 Nevertheless, many studies have shown that both aGVHD [10] [11] [12] [13] and chronic GVHD 11, 12, [14] [15] [16] were associated with a decreased RR in allogeneic BMT. Owing to the positive impact of the graftversus-leukaemia (GVL) effect associated with aGVHD on outcomes, aGVHD is desirable in patients transplanted for a malignant disease. However, grade III-IV aGVHD are associated with unacceptable TRM 15 and further studies are needed to find the best CsA regimen allowing avoidance of severe aGVHD, but sparing the GVL effect. 17 Two randomized trials conducted in adults 18 and children 8 transplanted for acute leukaemia have demonstrated the crucial impact of CsA on aGVHD incidence and outcome. They showed both a decreased RR and an increased EFS in the group receiving a low-dose CsA regimen, but at the price of an increased occurrence of severe aGVHD. Owing to significant pharmacokinetic interindividual variability, 19 cyclosporine trough blood concentrations (TBC) are very different between patients receiving the same CsA regimen. A relationship has clearly been shown between CsA serum 20 or blood concentrations 21 and aGVHD incidence. Thus, the differences in clinical response between patients receiving the same CsA regimen 8, 18 can be partially explained by blood concentration values. Consequently, a goal-oriented monitored CsA dosing regimen may be more effective than a fixed CsA dosing regimen, for aGVHD prophylaxis as well as favouring an anti-leukaemic effect. Unfortunately, therapeutic ranges used to monitor CsA therapy remain empirical 22 and heterogeneous. 17 Only two studies, mainly performed in adults, have shown the positive impact of a monitored CsA regimen on aGVHD incidence and outcome, 23, 24 but the results cannot be transposed to children. As goal-oriented individualized CsA regimens require accurate knowledge of the values of effective blood concentrations, the aim of our study was to clarify relationships between TBC and aGVHD incidence, in a population including only children receiving allogeneic MSD-or UD-SCT.
Patients and methods

Patients and donors
From October 1997 to October 2001, 94 children (58 males and 36 females) aged 3 months to 18 years consecutively underwent allogeneic SCT in Debrousse Hospital (Lyon, France). Indications for transplantation were: malignant haemopathies (n ¼ 54), nonmalignant haemopathies (n ¼ 17), inborn errors of metabolism (n ¼ 14), immuno deficiencies (n ¼ 6) and others (n ¼ 3). In all, 39 children were transplanted from related donors: 36 were HLAidentical and three mismatched. A total of 55 children were transplanted from unrelated donors: 20 were HLAmatched for locus A, B and DR, and 35 were HLAmismatched on 1-3 loci. The stem cell source was: unmanipulated bone marrow for related donor-SCT (n ¼ 39); peripheral blood stem cells (n ¼ 2), cord blood stem cells (n ¼ 2) and unmanipulated bone marrow (n ¼ 51) for unrelated donor-SCT. Methods of HLA typing for patients and donors are described in detail by Souillet et al. 7 Patient and donor characteristics are described in Table 1 .
Conditioning regimen
Pretransplant conditioning consisted of TBI in conjunction with etoposide in 20 patients or other drugs in 12 patients. Other patients were conditioned with cytotoxic drugs alone: busulphan with cyclophosphamide (CY) in 41 patients or other drug(s) in 12 patients. CY was used alone in nine patients.
GVHD prophylaxis
In MSD-BMT, prophylaxis usually included CsA alone (n ¼ 9) or in conjunction with a short course of MTX (n ¼ 16). Patients transplanted for thalassemia received CsA with antithymocyte globulin (ATG) (Thymoglobuline s , Imtix Sangstat, Lyon, France) (n ¼ 6). ATG was given prior to transplant (total dose between 10 and 20 mg/kg) to obtain partial in vivo T-cell depletion. No GVHD prophylaxis was administered to three patients receiving a second MSD-BMT. Two patients received CsA with MTX and ATG. In UD-BMT, prophylaxis included ATG and MTX and CsA (n ¼ 34). Since October 2000, the use of MTX was stopped and prophylaxis included only CsA+ATG (n ¼ 21). The three patients transplanted from an MMRD received CsA+MTX+ATG. For most of the indications, CsA was given intravenously as an 8-h infusion (initial dose of 5 mg/kg/day, except for ALL: 3 mg/kg/day), starting on the day preceding transplantation. When oral medication could be tolerated, CsA was administered orally every 12 h at a dose calculated for each patient. The median Relationship between CsA TBC and severity of aGVHD P Martin et al day of conversion from intravenous to oral cyclosporine was day 14. The duration of CsA therapy was 3 months in ALL, 6 months in other malignant diseases and 9 months in nonmalignant diseases. It was extended by 3 months when aGVHD was diagnosed. A measure of 15 mg/m 2 of MTX was administered intravenously on day 1 and 10 mg/m 2 on days 3, 6 and 11 (except for Fanconi anaemia: only three doses). When gastrointestinal toxicity occurred, only three doses of MTX were administered.
CsA assay in whole blood
Measurements of cyclosporine blood concentrations were performed by immuno-enzymatic assay (EMIT on Cobas MIRA analyser, Behring Diagnostic, France). The limit of detection was 30 ng/ml. The analytical error assay pattern could be described by the following relationship: s.d. ¼ 0.001460+0.034560 Â C (where s.d. is the standard deviation of the measurement and C the measured concentration). During intravenous treatment, the CsA blood concentration was measured twice weekly from day +1 after transplantation using peripheral venous blood samples. After the switch IV-oral, CsA blood concentration was measured twice weekly during the first month post transplantation, using central venous samples (except the three first days after the switch, when peripheral venous samples were used).
Individualization of CsA regimen
A computer file was made for each patient starting CsA therapy, by using the file manager program (PASTRX) included in the USC*PACK software. 25 Each file contained anthropometric and treatment data such as age, weight, administered amounts of CsA, time of administration, infusion duration, blood sampling times and drug blood level measurements. The individual pharmacokinetic parameter values were then estimated for a two-compartment model, using a MAP (Maximum A Posteriori) Bayesian method also implemented in USC*PACK. 26 This method allows accurate estimation of the whole drug blood concentration vs time profile from only one to three drug blood level measurements, by combining available patient information and population information (defined as the distribution of pharmacokinetic parameter values obtained from similar patients treated previously). Moreover, the analytical error is taken into account to determine pharmacokinetic parameter values, as each drug concentration measured is weighted by the reciprocal of the variance associated with the assay described above. This permits a credibility level to be attributed to each measured blood concentration, increasing the accuracy of the estimates. 27 Individual pharmacokinetic parameter values are then used to simulate future CsA blood concentrations and consequently determine the doses necessary to reach CsA target blood concentrations at any time. As no precise data on efficient blood concentrations were available in this population, the choice of target values was based on our experience. Indeed, we used approximate and intuitive target CsA trough blood levels as no data concerning real antileukaemic or anti-GVHD values were available for children. The principle was to target below a value of 100 ng/ml (around 60-100 ng/ml) when an anti-leukaemic effect was needed, and above a value of 100 ng/ml (around 100-150 ng/ml) when an anti-leukaemic effect was not necessary.
Relationship between CsA and aGVHD
The mean TBC has been retrospectively estimated for each patient by the MAP Bayesian modelling procedure, for different durations of post transplantation exposure to CsA: (1) first week, (2) second week, (3) mean of the first two weeks and (4) week with the lower TBC among both. For patients who developed aGVHD, two 'dependent-time' periods of CsA exposure have been studied: (5) the week before the onset of aGVHD and (6) total duration from transplantation until onset of aGVHD.
All statistical analyses were performed using SPSS for Windows (version 9.0, SPSS, Chicago, IL, USA).
Grading of acute GVHD
Acute GVHD was graded according to Glucksberg et al 28 and confirmed by appropriate histological studies. All cases of GVHD occurred in the early post transplantation period.
Results
In MSD-SCT (n ¼ 36), the incidence of aGVHD was 44.4%: grade I: 19.4% (n ¼ 7), grade II: 11.1% (n ¼ 4), grade III: 2.8% (n ¼ 1), grade IV: 11.1% (n ¼ 4). Table 2 gives details of the incidence of aGVHD in malignant and nonmalignant diseases. The incidence of grade II-IV aGVHD was higher in malignant diseases (31.6%) compared to nonmalignant diseases (17.7%). Five patients suffered from severe aGVHD. Incidence of mild aGVHD was 31.6% (n ¼ 6) in malignant diseases but only 5.6% (n ¼ 1) in other indications. Incidence of aGVHD was 47.5% in HLA nonidentical SCT (MMSD-and UD-SCT): grade I: 28.8% (n ¼ 17), grade II: 11.9% (n ¼ 7), grade III: 5.1% (n ¼ 3), grade IV: 1.7% (n ¼ 1). As previously reported in MSD-SCT, aGVHD was more frequent in malignant diseases (22.5%) than in nonmalignant diseases (12.5%). Mild aGVHD was frequent in both subgroups, respectively 28.6% (n ¼ 10) and 29.2% (n ¼ 7). Only four cases of severe aGVHD occurred.
TBC corresponding to various periods after transplantation in patients who developed grade II-IV aGVHD vs 0-I are shown in Table 3 . In MSD-SCT, results indicated that TBC were lower for all periods studied in patients who developed grade II-IV aGVHD compared to those without GVHD or with grade I. As shown in Table 4 , the trend was not significant in HLA nonidentical SCT. However, TBC were significantly lower in patients with grade I-IV aGVHD vs those without aGVHD. Relationships between TBC and the grade of aGVHD for all patients (n ¼ 95) are shown in Table 5 and Figure 1 . The mean TBC during the first two weeks was 10178 ng/ml in patients without aGVHD, 7778 ng/ml in patients developing mild aGVHD, 6178 ng/ml in those with moderate aGVHD and 56710 ng/ml in those with severe aGVHD. During the second week, TBC were slightly higher than during the first week (except in patients without aGVHD), probably because many patients who developed aGVHD during the second week received higher doses of CsA as a curative treatment. Our results indicate a significant correlation for all the periods studied. Despite the variability of TBC between patients developing the same grade of aGVHD, mean differences of around 20-25 ng/ml were found between patients without aGVHD and those developing mild aGVHD. Between mild and moderate aGVHD, the difference was around 15-20 ng/ml. On the other hand, the difference between TBC was slight between patients with moderate, and those with severe aGVHD. With respect to the 'dependent-time' periods studied: the week preceding the onset of aGVHD and the period from the day of transplant until aGVHD, TBC were similar to the first week post transplantation. For different ranges of TBC (o65; between 65 and 85, and 485 ng/ml) corresponding to the first two weeks after transplantation, the number of patients developing aGVHD was calculated. Above 85 ng/ ml, no moderate to severe aGVHD occurred. Indeed, above this threshold, patients developed no aGVHD (14 matched sibling and 16 unrelated or mismatched-related SCT) or only mild aGVHD (three and seven patients, respectively). Between 65 and 85 ng/ml, grade II-IV aGVHD was also found in MSD-SCT (n ¼ 2) as well as in unrelated or mismatched-related SCT (n ¼ 5). TBC between 65 and 85 ng/ml remained effective in the majority of MSD-SCT: five patients without aGVHD, one developing mild and two moderate to severe aGVHD, but not in HLA nonidentical SCT: six patients without aGVHD vs four with mild and seven with moderate to severe aGVHD. Below 65 ng/ml, the majority of patients developed aGVHD after MSD-SCT: three mild and seven moderate to severe aGVHD vs one patient without aGVHD. CsA remained effective in eight patients developing no aGVHD and six patients developing mild aGVHD after HLA nonidentical SCT, but its activity was inconsistent: four patients developed moderate to severe aGVHD.
Discussion
GVHD prophylaxis used in the patients included in this study appears heterogenous. However, we chose to keep them all as a previous analysis performed on this cohort showed that, among many clinical and pharmacological risk factors for aGVHD occurrence, the trough blood concentration of cyclosporin was a major one (data submitted for publication). Risk factors for aGVHD tested were: pharmacological qualitative factors ('immunosuppression with CsA alone vs CsA associated to MTX') and quantitative factors focused on CsA exposure (peak and trough blood concentration, area under the concentration curve vs time) and clinical factors (recipient age, recipient sex, donor age, donor sex, female donor-male recipient vs other combinations, sex match vs sex mismatch). In the same way, the influence of HLA mismatches in unrelated donors was revealed as poor when ATG was given at high doses (20 mg/kg), leading us not to consider this factor in the present study. These unexpected results were subsequently confirmed in our clinical practice, where occurrence of GVHD could be managed in a majority of our patients just by closely controlling the values of trough blood concentrations (two or three times a week in the very early post transplantation period). In this study, trough blood levels were retrospectively calculated by an MAP Bayesian procedure. The use of this method has been demonstrated for cyclosporine 29, 30 and it is expected that dosing of the drug as a result is more accurate since analytical error is taken into account. 27 Early studies showed no correlation between CsA blood concentrations and aGVHD incidence. [31] [32] [33] However, the CsA assay was not sufficiently specific before 1987 and studies included very few patients. The first correlation between TBC and aGVHD was established by Gluckman et al 34 but was general, showing only that patients with aGVHD had lower TBC. Other studies showed a lower risk of aGVHD when the CsA trough concentration was greater than 200-350 ng/ml by serum RIA 20, 35 or greater than 400 ng/ml by whole blood RIA 36, 37 in matched-sibling BMT. Przepiorka et al 38 and Ghalie et al 21 demonstrated a lower risk associated with TBC above 250 ng/ml and 200 ng/ml, respectively, during the first weeks after transplantation. CsA was associated with a short course of MTX as GVHD prophylaxis and TBC were measured by HPLC. In comparison with values found in previous studies, our results show that lower TBC during the intravenous treatment period were sufficient to prevent moderate to severe aGVHD, as well in MSD-as in UD-BMT. For TBC above 85 ng/ml during the first 2 weeks after transplantation, some patients suffered from mild aGVHD but no moderate to severe aGVHD occurred. These results can be explained by a lower mean recipient age in our cohort in comparison with others, including both adults and children, as recipient age is recognized as an important risk factor for aGVHD. 1, 3 Thus, children receiving allogeneic SCT could require lower CsA concentrations than adults. On the other hand, Bayesian pharmacokinetic monitoring of CsA dosage regimens allowed us to maintain target TBC more precisely and more accurately than with the usual empirical monitoring. This could contribute to sufficient cover of the patients with only 85 ng/ml, subject to reaching this target value as soon as possible during the first days post transplant and as regularly as possible during the first weeks. However, the choice of such low target CsA levels has to be balanced with the age of the recipient and the concomitant use of a variable number of high doses of ATG.
In MSD-BMT, a strong relationship between TBC values and aGVHD incidence was shown in our cohort despite a large diversity of prophylaxis. This strengthens the role of CsA as the mainstay of GVHD prophylaxis. In the same way, and for the first time, a relationship was Relationship between CsA TBC and severity of aGVHD P Martin et al found in unrelated donor SCT despite intensive immunosuppression including the in vivo T-cell depletion usually added to CsA and MTX. The trend toward a lower TBC observed in children with grade II-IV compared to children without or with mild aGVHD was not significant. However, TBC was significantly lower in children with grade I-IV aGVHD in comparison to those without aGVHD. Although some correlations between TBC and aGVHD incidence have been established in MSD-BMT, no data were available in UD-BMT. Two studies conducted on cohorts including a majority of adults showed a much higher incidence of grade II-IV aGVHD than did our cohort despite high TBC during the first 2 weeks after transplantation: 34% above 200 ng/ml 21 and 21% above 250 ng/ml, 38 respectively. Moreover, in our study all grade II-IV aGVHD occurred for TBC below 85 ng/ml, while almost no GVHD was observed for TBC around 110 ng/ml during the first 2 weeks after transplantation. This suggests better sensitivity and specificity of our threshold values, in the setting of precise Bayesian monitoring of CsA.
It has been established that RR is lower in patients with acute [10] [11] [12] [13] or chronic GVHD. 11, 12, [14] [15] [16] However, moderate and especially severe aGVHD are associated with high mortality in adults. 13, 39 In patients transplanted for CML or acute leukaemia, optimal leukaemia-free-survival (LFS) was obtained with mild aGVHD, in related 13, 15, 39 as well as in unrelated BMT. 40 On the other hand, the study of Gustafsson et al 9 suggested that only severe aGVHD must be avoided in children but not mild or moderate aGVHD. Unfortunately, no method is known to prevent only severe aGVHD and uncertainties remain concerning the choice of an optimal CsA regimen to reach this objective. Some randomized prospective trials assessed the effect of a lowdose CsA regimen (1 mg/kg/day intravenously) in leukaemic patients and showed a significant decrease in RR, but an increased incidence of grade II-IV aGVHD 8, 18 and associated mortality. 18 Finally, these trials showed the limits of a fixed CsA dosing regimen, in preventing relapses without increasing severe aGVHD. These discrepancies in clinical response are not surprising considering the CsA pharmacokinetic variability. Until this study, no clear relationship had been established between immunosuppressive therapy and severity of aGVHD. Despite the association to other immunosuppressive drugs and individual risk factors for aGVHD, we found a significant relationship between TBC during the early period after transplantation and the severity of aGVHD, as the lower the TBC, the more severe is the GVHD.
The correlation between the period of time after transplantation and the risk of aGVHD has been widely discussed. Yee et al 20 have found a relationship for the week before the onset of aGVHD. According to Schmidt et al, 35 TBC were decreased during the days preceding the onset of severe aGVHD. In the study of Przepiorka, et al, 38 TBC during the second week post transplant were lower in patients developing grade II-IV aGVHD, and according to Santos et al, 41 CsA exposure during the first week is essential. Results of Ghalie et al 21 showed an increased risk for GVHD when TBC were too low during the week preceding engraftment. Bacigalupo et al 18 showed a higher risk for aGVHD in the group receiving the low-dose CsA regimen during the three first weeks after transplantation. Our results indicated a significant relationship for some of the periods studied: 'time-independent' periods: first and second week after the transplant, and 'time-dependent' periods: week before the onset of aGVHD and the period post transplant preceding the diagnosis of aGVHD. These results suggest that close monitoring of CsA therapy may be essential during the first weeks post transplantation and particularly during the second week, corresponding usually to the period preceding engraftment. Despite the crucial role of TBC during the early post transplant period, the methods of TBC monitoring during this period are quite variable and not consensual. 17, 42 Only two studies have reported a positive impact of monitored and individualized CsA therapy on the incidence of aGVHD and outcomes. 23, 24 However, TBC usually targeted seem very likely to be associated with possible excessive immunosuppression, enhancing the incidence of infections (around 150-180 ng/ml), or the range maybe too wide (95-205 ng/ml). The strong relationship established in our study between TBC and severity of aGVHD allows us to suggest a target CsA blood concentration value rather than a range: TBC of 110 ng/ml in nonmalignant diseases and TBC of 80 ng/ml in malignant diseases. These target concentrations should be considered only in paediatric cases and balanced with the use of ATG and the CsA assay method. Furthermore, this low targeting could be interesting with respect to avoiding infectious complications, but this requires assessment.
In conclusion, the early post transplantation period of CsA exposure seemed crucial in relation to aGVHD incidence: it could be decisive to adjust TBC correctly during this time. Instead of changing the CsA regimen after noting an inappropriate TBC value in any patient, it may be more efficient to forecast future CsA concentrations and to select the best regimen to achieve target blood levels. This can be performed with MAP Bayesian fitting procedure, which can be used with a single blood concentration measurement and without waiting for a steady state.
